Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?

Shiyu Yang, Xia Jiang, Haihui Zhuang, Fenglin Li, Ying Lu · 2024

Read Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey? by Shiyu Yang, Xia Jiang, Haihui Zhuang, Fenglin Li, Ying Lu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590347.txt.

Description

Shiyu Yang, Xia Jiang, and co-authors map the drug trial field for a slow blood cancer in a note to peers, in a 2024 letter. Key block drugs made most sick folks live near as long as well kin. Yet firm, back slide, and march cases still lack wide drug picks in wards.

A trade bank read finds more than a score and a half of trials to a set fall date. Trial counts stay high year to year with a slight late dip. Most trials sit in the first two test grades by far. Mark drugs rule the field past the first win year. New immune ways surge in late trial work.

Catalog record

CREATORShiyu Yang, Xia Jiang, Haihui Zhuang, Fenglin Li, Ying Lu
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11590347

Browse the full library · About the Tower of Babel